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Abstract:  Group  A  rotaviruses  are  a  major  cause  of  diarrhea  in  the  young  of  many 
mammalian species. In rotavirus infected piglets mortality can be as high as 60%. Previous 
research in this laboratory has identified a porcine intestinal GM3 ganglioside receptor that 
is required for sialic acid-dependent rotavirus recognition of host cells. In addition, we 
previously  demonstrated  exogenously  added  GM3  can  competitively  inhibit  porcine 
rotavirus  binding  and  infectivity  of  host  cells  in  vitro.  Sialyllactose,  the  carbohydrate 
moiety  of  GM3,  is  approximately  3  orders  of  magnitude  less  effective  than  GM3  at 
inhibiting rotavirus binding to cells. Furthermore, production of therapeutic quantities of 
GM3 ganglioside for use as an oral carbomimetic in swine is cost prohibitive. In an effort 
to  circumvent  these  problems,  a  sialyllactose-containing  neoglycolipid  was  synthesized 
and  evaluated  for  its  ability  to  inhibit  rotavirus  binding  and  infectivity  of  host  cells. 
Sialyllactose  was  coupled  to  dipalmitoylphosphatidylethanolamine  (PE)  by  reductive 
amination  and  the  product  (SLPE)  purified  by  HPLC.  Characterization  of  the  
product  showed  a  single  primulin  (lipid)  and  resorcinol  (sialic  acid)  positive  band  by  
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thin  layer  chromatography  and  quantification  of  phosphate  and  sialic  acid  yielded  a  
1:1 molar ratio. Mass spectroscopy confirmed a molecular weight coinciding with SLPE. 
Concentration-dependent binding of rotavirus to SLPE was demonstrated using a thin-layer 
overlay assay. Using concentrations comparable to GM3, SLPE was also shown to inhibit 
rotavirus  binding  to  host  cells  by  80%.  Furthermore,  SLPE  was  shown  to  decrease 
rotavirus infection of host cells by over 90%. Finally, preliminary results of in vivo animal 
challenge studies using newborn piglets in their natural environment, demonstrated SLPE 
afforded complete protection from rotavirus disease. The efficacy of SLPE in inhibiting 
rotavirus binding and infection in vitro and in vivo, coupled with its relatively low-cost, 
large-scale  production  capabilities  make  SLPE  a  promising  candidate  for  further 
exploration as a possible prophylactic or therapeutic nutriceutical for combating rotavirus 
disease in animals. Most importantly, the results presented here provide proof of concept 
that the nutriceutical approach of providing natural or synthetic dietary receptor mimetics 
for protection against gastrointestinal virus infectious disease in all species is plausible. 
Keywords:  nutriceutical;  carbomimetic;  receptor  therapy;  neoglycolipid;  rotavirus; 
ganglioside; infectious; disease 
 
1. Introduction  
Rotaviruses are a major cause of diarrhea in the young of most mammalian species and the most 
important cause of severe dehydrating diarrhea in children worldwide. In excess of 60,000 deaths 
caused by rotavirus occur in infants and young children annually [1]. Neonatal piglets and calves are 
very susceptible to naturally occurring rotavirus disease that is often associated with recent weaning. 
While rotavirus infection is capable of causing significant morbidity and death loss, most infected 
piglets survive the infection but remain stunted as a result of villous blunting and fusion combined 
with maldigestion and malabsorption.  
Most  herds  are  infected  with  porcine  rotavirus,  especially  Group  A  strains,  and  there  is  a  
disease-producing  synergism  with  intercurrent  infection  with  other  enteropathogens.  Rotaviruses 
display a tropism for the villous enterocytes lining the small intestine. Productive infection results in 
cell lysis. Although some minor variations in the pathophysiological responses exist among species, 
the most prominent and consistent lesion is villous atrophy.  
Two  oral  human  rotavirus  (HRV)  vaccines  were  recently  licensed:  a  three-dose  human-bovine 
reassortant multivalent rotavirus vaccine, RotaTeqTM in the US, Canada and ~30 other countries; and 
a  two-dose  attenuated  HRV  (AttHRV)  monovalent  vaccine  (G1P1A(8)),  RotarixTM  in  more  than 
90 countries, including countries of the European Union, Latin America, Asia and Africa (for review 
see [2]). Both vaccines are highly effective against severe rotavirus disease and death in the developed 
world,  and  their  widespread  use  has  even  resulted  in  reduced  disease  rates  in  unvaccinated 
children [3]. These results are impressive; however, the protective efficacy of these live oral vaccines 
against cases of rotavirus diarrhea in the developing world is considerably reduced. For example, the 
approximate protection provided by Rotarix against severe rotavirus diarrhea was 49% in Malawi and Nutrients 2011, 3  
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77% in South Africa as compared to 96% in Europe [4,5]. Furthermore, gene reassortment occurs 
in vitro and in vivo between human and animal rotavirus [6,7]. With the advent of complete genome 
sequencing for rotaviruses, there are numerous reports in recent years describing animal/human RV 
reassortants which have emerged in nature from co-circulating and co-infecting rotaviruses (for review 
see [8]). Thus, use of HRV vaccines constructed using infectious animal rotaviruses introduces animal 
rotavirus  genes  into the human  population  (for review see [9]).  Although it is too early to know 
whether and to what extent the widespread use of HRV will lead to immune selection of new strains, 
there is the potential for vaccine-associated collateral infections especially in immunocompromised 
individuals [10]. In contrast to attenuated-live vaccines, the use of inactivated or non-replicative virus 
like  particles  (VLPs)  as  vaccine  candidates,  coupled  with  new  strategies  for  boosting  mucosal 
immunity,  [9,11–14],  and/or  direct  competition  with  virus-host  cell  binding  using  a  dietary 
nutriceutical approach, may have the greatest potential to provide stable, long-term protection against 
rotavirus disease in both animals and people. This approach also reduces the possibility of emergence 
of virus P and G types not represented in the vaccine strains since non-replicative virus particles will 
not reassort with wild type rotaviruses.  
Despite remarkable progress in rotavirus vaccine development for both animals [12,13,15–17] and 
humans [2,18–22], there are no effective commercial vaccines or licensed rotavirus-specific antiviral 
agents for animals in wide clinical use and no practical method of preventing rotavirus infection in 
swine  herds.  In  this  report,  we  provide  proof  of  concept  that  an  orally  administered,  synthetic, 
neoglycolipid can be used as a therapeutic receptor mimetic for the prevention of Group A rotavirus 
disease in neonatal piglets.  
2. Experimental Section 
2.1. Cells and Virus 
For all in vitro experiments, Group A porcine rotavirus (OSU strain (P9(7)G5)) was propagated in 
MA104  cells  (ATCC  HTB  37)  and  triple  and  double-layered  virus  particles  isolated  by  gradient 
purification  using  the  following  modification  of  standard  techniques  [23–25].  A  single  gradient 
centrifugation step was performed using a near vertical tube rotor (Beckman, NVT65) for 6.5 h, at 
60,000 rpm (291,110×  g) instead of dual gradient runs using an SW 55 swinging bucket rotor, at 
35,000 rpm, (116,140×  g), for 30 h. For in vivo studies, the above virus was passed in newborn piglets 
and partially purified from feces as previously described [26].  
2.2. Synthesis of Neoglycolipids 
Sialyllactose  or  lactose  was  linked  to  dipalmitoylphosphatidylethanolamine  (PE)  to  yield 
sialyllactosylphosphatidylethanolamine  (SLPE)  or  lactosylphosphatidylethanolamine  (LPE)  via 
reductive amination using modifications of a previously described procedure [27]. Briefly, 100 mg of 
sialyllactose (SL) or lactose was dissolved in DMSO (1 mL) and then mixed with 200 mg PE in 40 mL 
CHCL3:MeOH (2:1) under constant stirring in a round bottomed flask. The tube containing the SL was 
rinsed with methanol (5 mL) and added to the flask, and the reaction mixture was incubated at 60 °C  
for two hours. At the end of this incubation, 1 mL of reducing agent NaCNBH4, (10 mg) dissolved Nutrients 2011, 3  
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CHCl3:MeOH:acetic acid (2:1:0.001, v/v) was prepared fresh and added to the reaction mixture. Four 
more 1 mL aliquots of reducing agent were added to the reaction at approximately 4 h intervals and 
appearance  of  reaction  products  monitored  using  analytical  thin  layer  chromatography  (TLC)  and 
orcinol, resorcinol, and primulin sprays to identify bands containing neutral carbohydrate, sialic acid, 
and lipid, respectively. Following approximately 22 h total reaction time, the mixture was dried by 
rotary evaporation, dissolved in 20 mL water, and dialyzed against 5 L of H2O for 5 h. The dialysis 
was  repeated  twice,  the  sample  lyophilized,  and  the  SLPE  (or  LPE)  resuspended  in  25  mL 
CHCl3:MeOH:H2O (65:25:3, v/v) and purified using preparative HPLC (below).  
2.3. Purification of Neoglycolipids by Preparative HPLC 
Aliquots (5 mL) of SLPE or LPE were filtered 0.45 µm nylon filters and applied to 10 µm silica 
preparative HPLC column (250 mm ×  22 mm, Econosil, Alltech Associates, Inc., cat. #6258). The 
sample was applied to the column in CHCl3:MeOH:H2O (65:25:3, v/v) at a flow rate of 2 mL/min and 
eluted using the following sequence: 0–30 min, 100% CHCl3:MeOH:H2O (65:25:3, v/v); 30–75 min, 
a linear  gradient  of  CHCl3:MeOH:H2O  from  (65:25:3,  v/v)  to  (55:45:10);  75–120  min, 
100% CHCl3:MeOH:H2O  (55:45:10);  120–125  min,  a  linear  gradient  of  CHCl3:MeOH:H2O  from 
(55:45:10) to (30:60:20); and from 125 to 160 min, 100% CHCl3:MeOH:H2O (30:60:20). Fractions 
were  collected  every  2  min  and  continuously  monitored  by  stream  splitting  and  refractive  index 
measurements  using  an  evaporative  laser  light  scattering  detector  (Varex  ELSD  MK  III,  Alltech 
Associates,  Inc.).  Detector  settings  were  as  follows:  drift  tube  temperature  =  60  ° C,  exhaust 
temperature  =  35.9  °C ,  gas  (N2)  flow  rate  = 0.7–0.9  SLPM  and  pressure  =  6.8  psig; the  solvent 
pressure was 0.2 psig. Purity of the HPLC fractions and final SLPE or LPE pool was assessed by 
analytical TLC [23–25].  
2.4. Neoglycolipid Product Characterization  
For characterization of the purified SLPE or LPE reaction product, molecular mass and phosphate 
to sialic acid molar ratios were determined using the following assays. Sialic acid was determined by 
modification  of  an  HPLC/thiobarbituric  acid  method  [28].  Briefly,  following  acid  hydrolysis  and 
development  of  the  chromagen  as  originally  described,  100  µ L  aliquots  were  injected  and 
chromatographed through a 4.6 mm ×  250 mm C-18 reverse phase column (Alltech Associates, Inc.). 
The solvent (2×  buffer stock:MeOH:water, 5:3:2, v/v) was run isocratically using a Dionex DX300 
HPLC apparatus set at a flow rate of 0.7 mL/min and 549 nm for measuring absorbance of chromagen. 
Phosphate  content  was  measured  colorimetrically  [29]  and  molecular  mass  was  determined  using  
low-resolution  fast-atom  bombardment  mass  spectrometry  (FAB-MS)  at  the  Mass  Spectrometry 
Laboratory, School of Chemical Sciences, University of Illinois as previously described [30].  
2.5. Synthesis of Sialyllactosyl-BSA 
Sialyllactose  was  coupled  to  BSA  via  reductive  amination  as  previously  described  [31].  The 
Reaction product was extensively dialyzed versus water and then lyophilized. The average number of Nutrients 2011, 3  
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sialyllactose  residues  coupled  to  BSA  was  37  and  was  determined  following  acid  hydrolysis  by 
HPAEC-PAD monosaccharide analysis [25] and protein determination by bicinchoninic acid assay [32].  
2.6. Acetylation of PE and PE Derivatives 
Acetic  anhydride  was  added  in  five  portions  to  samples  containing  PE,  LPE,  and  SLPE  in  a  
1:1 chloroform:methanol solution containing sodium bicarbonate as previously described [33]. Tubes 
were  incubated  at  room  temperature  and  the  reaction  was  stopped  by  the  addition  of  water.  The 
reaction mixture was then extracted 3 times using CHCl3:MeOH:H2O at a final ratio of 1:1:1.1 (v/v), 
the  organic  layers  pooled  and  evaporated  to  dryness.  Reaction  products  were  characterized  using 
analytical TLC [24,25].  
2.7. Virus Radiolabeling and Host Cell Binding Assay  
Virus (TLP) radiolabeling with 
125I was performed as previously described [23,25]. Viral protein 
was quantified colorimetrically [32] with human serum albumin as the standard (Micro BCA; Pierce 
Chemical, Co.). Measurement of virus binding to MA104 cells in the absence or presence of added 
gangliosides  or  other  glycoconjugate  inhibitors  was  performed  based  on  the  results  of  binding  
kinetic  and  virus  dose  experiments  as  previously  described  [25].  VP6  was  released  from  porcine  
double-layered rotavirus particles (DLP) after treatment with 1 M CaCl2 as previously described [34]. 
Briefly, 400 µg  DLP from porcine OSU strain in 3 mL TNC buffer (50 mM Tris, 150 mM NaCl, 
10 mM CaCl2, pH 7.5) were sonicated as described. The sample was made 1 M in CaCl2 by addition of 
440 mg CaCl2 and was incubated at 37 ° C for 20 min. After sonication, the sample was centrifuged at 
192,000×  g  for  1  h  at  4  ° C  to  separate  the  core  particle  (pellet)  from  released  VP6  proteins 
(supernatant). The supernatant was dialyzed against distilled water at 4 ° C. After concentration by 
evaporation  with  a  gentle  stream  of  air,  protein  concentration  was  determined  and  10  µg   was 
radioiodinated  as  described  above.  SDS  PAGE  and  autoradiographic  visualization  of  separated 
radioactive proteins was performed using standard techniques as previously described [35].  
2.8. Virus-Glycolipid Binding Assay 
Measurement of 
125I-labeled rotavirus (TLP) binding to immobilized gangliosides (0.5–10 nmol) or 
neoglycolipids (SLPE, LPE, or acetylated derivatives (~750 pmol)) was measured using a thin-layer 
plate overlay assay as previously described [25]. Briefly, glycolipids were applied to the origin of a 
plastic-backed silica gel TLC plate which had been pre-run in chloroform-methanol (MeOH)-H2O 
(60:30:4.5, v/v). The plate was developed in chloroform-MeOH-H2O (55:45:10), and after it was air 
dried, overlay of the 
125I-labeled rotavirus was performed by a modification of a previous method [36]. 
The developed plate was treated with ice-cold TNC-BSA buffer (TNC plus 1% bovine serum albumin 
(Sigma; catalog No. 7030)) for 1 h at 4 ° C. The plate was then rinsed quickly in TNC buffer, placed in 
a glass dish with 7 mL of TNC containing 1.25 ×  10
7 dpm (~3 µg  of viral protein) of 
125I-labeled 
rotavirus (TLP)/100-cm
2 plate, and gently rocked for 2.5 h at 4 ° C. The 
125I-rotavirus overlay was 
removed by aspiration, and the plate was rinsed seven times in 400 mL of ice-cold filtered TNC. After 
air drying for 1 h at room temperature, the plate was wrapped in plastic, placed in a Cronex Lightning Nutrients 2011, 3  
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Plus cassette with intensifier screens, exposed to Kodak X-Omat film at −80° C for 4 h, and developed 
in an automatic developer.  
2.9. Measurement of in Vitro Virus Infectivity: Focus-Forming Assay  
Virus focus forming unit (FFU) assays were performed using confluent monolayers of MA104 cells 
in 24 well plates as previously described [25]. Briefly, gradient purified triple-layered virus particles 
were  treated  with  trypsin  (Sigma  T0134,  porcine  pancreas  at  a  final  concentration  of  10  µ g/mL 
(152 BAEE units/mL)) for 30 min at 37 C. Dilution of the trypsinized virus was performed to yield 
approximately 500 FFU/100 µ L. Aliquots of diluted virus were incubated with either PE, glyco-PE 
derivatives, gangliosides, or were sham-treated for 15 min on ice. Treated virus suspensions (100 µL) 
were inoculated into wells followed by incubation at 37 ° C for 30 min. One milliliter of ice cold MEM 
was then added, aspirated and replaced with 1 mL of fresh MEM. The plates were warmed to 37 ° C 
and incubated as described above for 16–18 h. Virus infectivity was quantified using rotavirus-specific, 
immunoperoxidase histochemical staining and counting of stained foci under light microscopy. 
2.10. Animal Infectivity Experiments  
Term pregnant normal, rotavirus antibody negative sows (University of Illinois Veterinary High 
Health, Swine Herd) were induced to labor approximately 18 h prior to farrowing. Before the newborn 
piglets were allowed to nurse, one group from the litter was inoculated with rotavirus doses ranging 
from 1 ×  10
3 to 1 ×  10
5 focus forming units (FFU)/mL MEM per os. Another set of piglets from the 
same  litter  was  orally  inoculated  with  the  identical  virus  doses  as  the  first  set  but  including  
1–2 µmol SLPE/mL MEM (in separate experiments) either as a single dose or by continuous feeding 
(every  12 h).  All  piglets  were  dosed  within  2  h  of  birth.  The  piglets  were  then  returned  to  their 
respective sow and littermates housed in separate crates (for SLPE versus control (MEM) fed groups), 
but in the same farrowing room, for the remainder of the experiment. This experimental design was 
used  in  an  effort  to  mimic  the  environment  found  in  commercial  pig  production  facilities.  Fecal 
material  from  each  piglet  was  collected  by  anal  swab  24–96  h  after  initial  virus  inoculation  and 
enzyme linked inmunoassays (ELISA), for detection of rotavirus antigen (group A-specific), were 
performed  on  the  collected  fecal  material  using  an  IDEIA  kit  (cat.  #K6020,  DakoCytomation) 
according  to  manufacturer’s instructions.  In some experiments,  piglets  were euthanized  at various 
times postinoculation, intestinal contents collected, and sections of small intestine were processed for 
immunohistochemistry to localize rotavirus antigen as previously described [37]. Sows were sold and 
not returned to the herd at the conclusion of the experiments. All animal procedures described in this 
study were performed in accordance with protocols approved by the University of Illinois Institutional 
Animal Care and Use Committee (IACUC). 
3. Results and Discussion 
3.1. Synthesis, Purification, and Characterization of Sialyllactosylphoshatidylethanolamine  
Our earlier results [25] demonstrated that GM3, particularly N-glycolylGM3, ganglioside serves as a 
primary intestinal receptor for porcine Group A (OSU) rotavirus. In addition, we demonstrated the Nutrients 2011, 3  
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binding affinity for free sialyllactose, the virus binding epitope of GM3, was three orders of magnitude 
lower  than  for  the  intact  ganglioside  [35].  Based  on  these  results  and  the  desire  to  produce  an 
efficacious  receptor  mimetic  to  protect  against  rotavirus  disease,  we  set  out  to  synthesize  a 
neoglycolipid, receptor mimetic that could mimic the activity of the natural ganglioside receptor and 
be produced in large enough quantities for use as a possible nutriceutical. In devising the synthetic 
scheme for this neoglycolipid (Figure 1) we sought to reproduce the amphipathic character of the 
natural GM3, ganglioside receptor, by substituting the sphingosine lipid moiety of GM3, which is not 
directly involved in virus binding, with a readily-available lipid such as phosphatidylethanolamine that 
contains a reactive functional group, e.g., an amino group. We previously hypothesized the function of 
the lipid moiety of GM3, relative to its ability to inhibit rotavirus infectivity of host cells, is to enable 
presentation of the sialyllactose virus-binding epitope in multivalent form in aqueous media. This 
multivalent presentation is likely responsible for the observed increased virus binding avidity of GM3 
compared to free sialyllactose [25]. Accordingly, synthetic sialyllactosylphosphatidylethanolamine (SLPE) 
was designed to contain the sialyllactose virus-binding epitope coupled to phosphatidylethanolamine 
in an effort to mimic the amphipathic nature of the native ganglioside receptor. For this purpose,  
a one-step reductive amination synthesis scheme was used as previously described [27,38].  
Figure 1. Scheme for synthesis of SLPE. SLPE is synthesized using a one step reductive 
amination  to  covalently  couple  the  amino  group  of  phosphatidylethanolamine  to  the 
anomeric carbon of the reducing end glucose residue of sialyllactose.  
 
Characterization  of  the  reductive  amination  product  by  thin-layer  chromatography  (TLC)  of 
aliquots, taken at various times during the reaction, show clear development of a major primulin (lipid) 
and  resorcinol  (sialic  acid)  staining  band  (Figure  2).  Also,  complete  disappearance  of  the  initial 
sialyllactose band in the reaction mixture is evident after 13.5 h incubation. Following purification of Nutrients 2011, 3  
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the putative SLPE product by preparative HPLC (Figure 2), pooled HPLC fractions show a single 
primulin and resorcinol positive band with no traces of PE or sialyllactose present (Figure 3). The 
molar ratio of phosphate to sialic acid in this product was 1:1. Similar results were obtained for the 
synthesis  of  LPE  using  the  same  reductive  amination  conditions  but  substituting  lactose  for 
sialyllactose. Characterization of this product using orcinol (neutral sugar) and primulin staining for 
TLC as well as quantification of the molar ratio of galactose and phosphate in the purified HPLC 
fraction (1:1 galactose:phosphate, data not shown) indicated the expected product was obtained. 
Figure  2.  SLPE  synthesis  time  course  and  purification.  (A)  aliquots  of  the  reductive 
amination reaction were spotted on TLC plates and stained with primulin followed by 
resorcinol to detect lipids and sialic acid, respectively. Dark bands are resorcinol positive 
while circled areas correspond to primulin staining bands; (B) purification of SLPE by 
preparative HPLC was performed as described in the Experimental Section. Fractions from 
104–112 min were pooled and analyzed for SLPE purity by analytical TLC (Figure 3).  
   
Figure 3. Evaluation of the purity of SLPE. The purity of SLPE following synthesis and 
HPLC  purification  was  assessed  by  analytical  TLC  as  described  in  the  Experimental 
Section. (A) TLC chromatogram stained by resorcinol spray to detect sialic acid-containing 
bands. The chromatographic mobility of SLPE is shown along with standard PE and SL. 
(B)  a  parallel  chromatogram  as  described  in  A  was  run,  stained  with  primulin,  and 
photographed under UV light to detect lipid-containing bands.  
 
A  B 
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Finally, low  resolution FAB  mass  spectroscopy of the purified SLPE fraction  yielded  a  parent  
ion  of  1308.3  with  corresponding  sodium  salt  peaks  of  1330.3,  1352.3,  and  1374.3  (Figure  4A).  
This  parent  ion  molecular  mass  corresponds  to  the  molecular  mass  of  the  proposed  
sialyllactosyl-dipalmitoylphosphatidylethanolamine  product.  Similar  results  were  obtained  for  the 
purified LPE reaction product (Figure 4B) and a parent ion mass of 1019.1 with sodium salt peaks  
of  1041.1  and  1063.  These  values  are  in  agreement  with  the  predicted  molecular  mass  of 
lactosyldipalmitoylphosphatidylethanolamine.  
Figure 4. Characterization of SLPE and LPE by FAB mass spectrometry. Low resolution 
FAB  mass  spectrometry  was  performed  on  TLC/HPLC-purified  SLPE  and  LPE  as 
described in the Experimental Section. (A) SLPE; (B) LPE.  
 
3.2. Rotavirus Binding to SLPE and LPE Neoglycolipids  
To determine if rotavirus was able to recognize either SLPE or LPE we used TLC overlay binding 
assay as described in the Experimental Section. Rotavirus bound to SLPE in a concentration-dependent 
manner  (Figure  5A).  Interestingly,  rotavirus  appeared  to  bind  with  slightly  greater  affinity  to  the 
acetylated derivative of SLPE. This may be due to the removal of the amino group positive charge by 
N-acetylation. Although, the impact of N-acetylation on SLPE function as a receptor mimetic was not 
further explored in this study, it may be worthwhile in future studies to examine additional SLPE 
derivatives in attempts to further enhance rotavirus binding affinity. Rotavirus also bound to both LPE 
and acetyl-LPE, although this binding appeared weaker than to SLPE. The binding to LPE derivatives 
is likely due to the asialoganglioside specific binding activity of rotavirus double layered particles [39] 
which we show is attributable, at least in part, to inner capsid protein VP6 (Figure 5B). No rotavirus 
binding was observed for PE, acetyl-PE, or Di-lactosylPE (DiLPE) (Figure 5B).  
3.3. SLPE Inhibits both Rotavirus Binding and Infectivity of Host Cells in Vitro  
SLPE displayed dose-dependent inhibition of both rotavirus binding and infectivity of MA104 cells 
that was comparable to native GM3 ganglioside (Figure 6). SLPE inhibited approximately 90% of 
virus binding and infectivity of MA104 cells at concentrations of 25 and 80 µ M, respectively. The 
A  B Nutrients 2011, 3  
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inhibitory concentration for 50% inhibition of virus infectivity (IC50) was approximately 15 µM for 
SLPE as compared to 5 µM  for GM3. No inhibition of virus binding was observed for LPE, the 
neoglycoprotein sialyllactoseBSA, or PE.  
Figure 5. Binding of rotavirus to SLPE and LPE and their acetylated derivatives. Binding 
of  rotavirus  (TLP)  to  the  indicated  neoglycolipids  and their  acetylated  derivatives  was 
performed  by TLC  overlay and SDS  PAGE as described in  the Experimental Section. 
Panel  A  shows  rotavirus  binding to  increasing  concentrations (0.5–10  nmol)  of  SLPE. 
Panel B compares the relative binding affinity of [
125I]rotavirus TLP to SLPE, LPE and 
their acetylated derivatives. Panel C depicts the binding of purified [
125I]VP6 protein to 
GM2 and asialo-GM1 ganglioside (GA1). Panel D shows the electrophoretic mobility and 
autoradiography of radioactive material recovered from the band (arrow) scraped from the 
GA1 lane of the TLC plate in Panel C. Panel E shows the separation and visualization of 
[
125I]rotavirus TLP proteins by SDS PAGE and autoradiography. Note the GA1 binding 
radioactivity recovered from Panel D co-migrates with rotavirus VP6 capsid protein.  
 
 
These results indicate the most potent inhibitors or rotavirus binding are glycolipids rather than 
glycoproteins even though the sialyllactoseBSA is multisubstitued with sialic acid epitopes. Somewhat 
surprisingly, LPE was shown to inhibit 50% of virus infectivity at concentrations 50 µM  or above. 
Similarly, acetyl-LPE also inhibited infectivity to a similar extent (data not shown). PE showed no 
significant inhibition of virus infectivity (Figure 6). The mechanism by which LPE inhibits rotavirus 
infectivity is unknown but intriguing given the fact it displays only weak binding to the virus in TLC 
overlay  assays  and  no  inhibition  of  virus-host  cell  binding  (Figure  6).  Others  and  we  
previously  demonstrated  purified,  non-infectious  rotavirus  double-layered  particles  (DLP)  bind 
B  C  D  E 
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asialogangliosides [35,39]. Here we demonstrate purified, radioiodinated VP6 binds asialoganglioside 
GA1 (Figure 5C). These results suggest the weak binding of rotavirus TLP to LPE observed in TLC 
overlay assays (Figure 5B), may involve VP6 binding to non-reducing galactose residues on LPE. 
Thus, it is possible LPE-mediated inhibition of virus infectivity may interfere with either virus entry or 
replication rather than initial, sialic acid-dependent binding and is an especially interesting hypothesis 
that may explain why LPE is able to partially block rotavirus infectivity without inhibiting host cell 
binding (Figure 6).  
Figure 6. Effect of SLPE and LPE on rotavirus binding and infectivity of MA104 cells. 
(A)  Virus  (RV  TLP)  binding  and  (B)  infectivity  of  MA104  cells  in  the  presence  and 
absence of various concentrations of SLPE, LPE, and other lipids or neoglycoconjugates 
were measured as described in the Experimental Section. (●), PE; (●), LPE; (●), SLPE; 
(●), NGcGM3; (●), Sialyllactose-BSA (SL-BSA). SL-BSA concentrations are based on µM  
equivalent of sialic acid.  
 
3.4. SLPE Inhibits Rotavirus Infection and Disease in Piglets  
For experiments aimed at testing the ability of the SLPE to block rotavirus infection in vivo, relative 
large  amounts  (~90  mg)  of  SLPE  were  produced  to  test  as  a  nutriceutical  for  protection  against 
rotavirus disease at the time of virus infection in neonatal piglets. In the first experiment, each piglet 
received either 1.0 µmol SLPE in MEM, or MEM alone, as a single dose per os at the time of virus 
inoculation. The presence of clinical signs was monitored for 88 h post-inoculation (PI) and virus 
shedding was measured at 40 h, 64 h, and 88 h as described in the Experimental Section. In the second 
and third experiment, each piglet was dosed with SLPE or MEM at the time of virus inoculation as 
described above and then again every 12 h for up to 96 h at which time all piglets were euthanized. 
Clinical signs, virus shedding and immunohistochemical detection of rotavirus in intestinal sections 
harvested  from  euthanized  piglets  were  analyzed  as  described  in  the  Experimental  Section.  The 
comparison of the amount of rotavirus shed in feces of experimental (+1.0 µ mol SLPE) and control 
piglets  (MEM  only),  at  40  h,  64  h,  and  88  h  post  infection  with  varying  amount  of  virus  
(1 ×  10
3–1 ×  10
5 FFU), is shown in Table 1.  
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Table 1. Effect of single dose SLPE on virus shedding in rotavirus inoculated piglets. 
Piglets 
Virus dose 
(FFU) 
SLPE 
(µ mol) 
ELISA 40 h PI 
(% control) 
ELISA 
64 h PI 
ELISA 
88 h PI 
Diarrhea 
1  1 ×  10
5  -  2.704 (100)  0.938  1.449  + 
2  1 ×  10
5  1.0  0.931 (34)  0.298  0  − 
3  1 ×  10
4  -  2.684 (100)  1.026  0.218  + 
4  1 ×  10
4  1.0  0.845 (31)  0  1.683  −, + (88 h) 
5  1 ×  10
3  -  2.520 (100)  0  0.009  + 
6  1 ×  10
3  1.0  0.390 (15)  0  1.358  −, + (88 h) 
This first experiment was designed to determine optimal virus dose and initially evaluate whether 
SLPE  afforded  any  protection  against  virus  shedding  and  diarrhea.  SLPE-treated  piglets  did  not 
develop  clinical  signs  of  rotavirus  disease  (diarrhea,  lethargic  or  huddling  behavior,  anorexia) 
compared to their littermates receiving only MEM, who developed watery diarrhea, fecal staining, 
huddling  behavior,  and  anorexia  beginning  24  h  post-inoculation.  Although  virus  shedding  was 
observed in piglets receiving a single dose of SLPE it was markedly (66–85%, depending on virus dose) 
reduced in SLPE fed piglets 40 h PI (Table 1). Virus shedding continued at 64 h post inoculation in the 
SLPE fed pig that received the highest dose of virus and the two SLPE-fed piglets receiving the lower 
virus  doses  shed virus  antigen again at  88  h  post  inoculation (Table 1).  Although the number  of 
animals in this initial experiment was small, comparison of the ELISA results at 40 h, 64 h and 88 h PI 
suggested the protection from initial rotavirus infection (or re-infection from littermates, see discussion 
below) and virus shedding afforded by a single dose of SLPE began to wane sometime after 40 h PI 
with the highest virus dose (1 ×  10
5 FFU).  
In  a subsequent experiment, 11  control  piglets (inoculated with 1  ×  10
5 FFU virus alone)  and 
9 experimental piglets (inoculated with 1 ×  10
5 FFU plus a single dose of SLPE (1 µmol)) were 
maintained on separate sows but in the same farrowing house. All control piglets displayed a positive 
fecal ELISA (average value = 0.727, range = 0.100–2.50) compared to none of the SLPE-treated 
piglets (average ELISA value = 0.001, range = 0.000–0.007) at 24 h post inoculation. At 48 h post 
inoculation; however, 6/9 SLPE-fed piglets had positive fecal ELISA values. Together, the results of 
these  two  experiments  indicated  a  single  dose  of  SLPE  provided  some  initial  protection  against 
rotavirus infection, as evidenced by the delay in virus shedding in feces, but was not able to provide 
sustained protection.  
Based on the above results, we tested whether continuous feeding SLPE (feeding every 12 h) would 
afford greater protection against rotavirus infection and disease. When SLPE (1 µmol) was fed every 
12 h post-inoculation for the duration of the experiment, virus shedding in feces was not detected in 
any of the experimental piglets (Figure 7). In contrast, all control piglets challenged with virus in the 
absence of SLPE feeding shed virus between 32 and 67 h and displayed clinical signs of rotavirus 
disease (diarrhea). The time of onset of fecal shedding and diarrhea in the control piglets (rotavirus 
only inoculated) was quite variable and may be explained by differences in colostrum intake or virus 
dose resulting from re-exposure through contact with diarrheic and virus shedding littermates. 
In the fourth experiment, SLPE (2 µmol) was continuously fed (every 12 h) for 96 h as described 
above. Again, rotavirus disease and virus shedding were not detected in piglets fed SLPE as compared Nutrients 2011, 3  
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to control piglets inoculated with virus alone (Figure 8). In the control piglets, the onset of rotavirus 
disease and virus shedding was again variable but all of these piglets shed virus at some point during 
the 96-h experiment (Figure 8). As was the case in the previous experiment (Figure 7), the onset of 
virus shedding was variable and is probably explained by different amounts of colostrum intake, or  
re-infection via transmission among littermates following initial virus inoculation. Such a scenario is 
likely since all piglets were returned to their respective sows following initial virus inoculation and 
after each feeding. Although both sows and litters (SLPE-fed and virus alone) were housed in separate 
crates, they were in the same farrowing room and shared a common air supply. Accordingly, these 
results are encouraging considering none of the SLPE-fed piglets developed disease or shed virus 
despite the potential of being exposed to rotavirus from the neighboring virus-shedding control piglets. 
Figure 7. Effect of continuous feeding SLPE on virus shedding in rotavirus inoculated 
piglets. Piglets were inoculated with rotavirus (1 ×  10
5 FFU) in the presence or absence of 
SLPE (1 µ mol) fed every 12 h, and virus shedding in feces determined as described in the 
Experimental Section. 
 
Figure  8. Effect of feeding SLPE (2 µ mol) every 12 h on virus shedding in rotavirus 
inoculated piglets. Piglets were inoculated with rotavirus (1 ×  10
5 FFU) in the presence or 
absence of SLPE fed every 12 h, and virus titers in feces collected at the indicated times 
determined as described in the Experimental Section.  
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Finally,  rotavirus  infection  was  clearly  evident  following  immunohistochemical  staining  of 
intestinal  tissue  harvested  from  control  virus-infected  piglets,  but  not  in  virus-inoculated  piglets 
continuously fed SLPE (Figure 9). In piglets infected with rotavirus but in the presence of 1–2 µ mol of 
SLPE and then repeatedly fed SLPE every 12 h, almost no infected enterocytes were detected in 
intestinal tissue. Although we have not conducted separate experiments designed to evaluate the safety 
of continuously feeding SLPE to newborn piglets, we found no evidence of any toxicity associated 
with SLPE feeding in virus-inoculated piglets prior to virus shedding or development of diarrhea. 
SLPE piglets behaved normally and continued to gain weight (0.058 kg/day) comparable to piglets not 
receiving SLPE (0.048 kg/day). Clearly, studies aimed at evaluation the safety of SLPE feeding need 
to be conducted prior to performing large scale clinical or field efficacy trials. 
Figure  9.  Effect  of  SLPE  feeding  on  immunohistochemical  detection  of  rotavirus  in 
intestinal  tissue  from  rotavirus-infected  piglets.  Piglets  were  inoculated  with  rotavirus  
(1 ×  10
5 FFU) in the presence of MEM or SLPE (2 µmol) and fed MEM or SLPE (2 µmol) 
every  12  h,  euthanized  28–96  h  post-inoculation,  and  intestinal  tissue  harvested  and 
processed  for  immunohistochemical  detection  of  rotavirus  antigen  as  described  in  the 
Experimental  Section.  Typical  photomicrographs  of  immunohistochemically  stained 
sections of small intestinal segments from control and SLPE-fed, virus-infected piglets are 
shown below. (A) rotavirus-inoculated pig fed MEM (40 h); (B) rotavirus-inoculated pig 
fed SLPE (40 h).  
 
4. Conclusions 
Our findings demonstrate a dramatic reduction in virus shedding and absence of rotavirus disease in 
SLPE-fed piglets, thus providing “proof of concept” that a nutriceutical approach of using natural or 
synthetic receptor mimetics, such as SLPE, hold substantial promise for the prevention of rotavirus 
disease. This approach may be applicable not only to piglets in a natural field setting, but also as a 
potential dietary supplement, for example in infant formulae, for the prevention of rotavirus or other 
gastrointestinal infectious diseases in human infants.  
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